1. 1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. (September 2015) Authors: Sotiriou, C.; Venet, D.; Fumagalli, D.; Maetens, M.; Rothé, F.; Ignatiadis, M.; Bradbury, I.; Harbeck, N.; Gomez, H.; Chang, T.W.; Coccia-Portugal, M.A.; Di Cosimo, S.; De Azambuja, E.; De la Pena, L.; Nuciforo, P.; Armour, A.; Eidtmann, H.; Baselga, J.; Piccart, M.; Loi, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients. (September 2015) Authors: Sauri, T.; Macarulla, T.; Sanz-Garcia, E.; Moreno, D.; Vilaro, M.; Vivancos, A.; Elez, E.; Argil és, G.; Grasselli, J.; Capdevila, J.; Alsina, M.; Hierro, C.; Matos, I.; Dientsmann, R.; Nuciforo, P.; Tabernero, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S470 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors. (September 2015) Authors: Azaro, A.; Rodon, J.; Herranz, M.; Nuciforo, P.; Prudkin, L.; Lopez-Busto, N.; Balandraud, S.; Cattan, V.; Jacquet-Bescond, A.; Marfai, L.; Pauly, J.; Postel-Vinay, S.; Hollebecque, A.; Soria, J.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Mutational profile applicability in the prognosis of resected colorectal liver metastases beyond the classical clinical risk score. (September 2018) Authors: Dopazo-Taboada, C.; Sauri, T.; Herrando, A.; Hernández, J.; Vivancos, A.; Nuciforo, P.; Charco, R.; Dientsmann, R.; Tabernero, J.; Elez, E. Journal: HPB Issue: Volume 20(2018)Supplement 2 Page Start: S351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. (October 2020) Authors: Nuciforo, P.; Townend, J.; Saura, C.; de Azumbaja, E.; Hilbers, F.; Manukyants, A.; Werutsky, G.; Bliss, J.; Moebus, V.; Colleoni, M.; Aspitia, A.Moreno; Di Cosimo, S.; Van dooren, V.; Kroep, J.; Ferro, A.; Cameron, D.; Gelber, R.; Piccart-Gebhart, M.; Huober, J. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs). (October 2022) Authors: Bernatowicz, K.; Vieito, M.; Berche, R.; Alonso, G.; Galvao, V.; Oberoi, H.K.; Braña, I.; Saavedra, O.; Muñoz-Couselo, E.; Grussu, F.; Belen, A.; Serna, G.; Rotxes, M.; Sanz, M.; Tabernero, J.; Toledo, R.; Nuciforo, P.; Garralda, E.; Perez-Lopez, R. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. (April 2018) Authors: Prat, A.; Brase, J.C.; Cheng, Y.; Nuciforo, P.; Paré, L.; Pascual, T.; Martinez, D.; Galvan, P.; Vidal, M.; Adamo, B.; Hortobagyi, G.; Baselga, J.; Ciruelos, E. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (23rd September 2016) Authors: Shi, W.; Jiang, T.; Nuciforo, P.; Hatzis, C.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Peña, L.; Loi, S.; Rosa, D. D.; Chia, S.; Wardley, A.; Ueno, T.; Rossari, J.; Eidtmann, H.; Armour, A.; Piccart-Gebhart, M.; Rimm, D. L.; Baselga, J.; Pusztai, L. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PI3K blockade reverses primary resistance and adaptation to eribulin in PI3K-pathway activated breast cancer tumors. (July 2016) Authors: Gris-Oliver, A.; Saura, C.; Oliveira, M.; Piris, A.; Nuciforo, P.; Pérez-García, J.; Arribas, J.; Baselga, J.; Cortés, J.; Serra, V. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer. (April 2018) Authors: Fasani, R.; Comerma, L.; Pagliuca, F.; Thyparambil, S.; Peg, V.; Jimenez, J.; Cecchi, F.; Hembrough, T.; Perez, J.; Arribas, J.; Cortes, J.; Scaltriti, M.; Saura, C.; Nuciforo, P. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗